Preliminary Topline Results for Tislelizumab in Classical Hodgkin Lymphoma

A pivotal phase 2 trial indicates promise for another checkpoint drug, this time for patients with classical Hodgkin lymphoma.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2O8l2L3